Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.